Reaxys
PubChem
eMolecules
Reactions (59)
Substances (1)
Structure
Citations (74)
Structure/Compound Data Chemical Name: (R)-2-methylamino-1-phenylpropane Reaxys Registry Number: 3081879
CAS Registry Number: 33817-09-3 Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H15N Molecular Weight: 149.236 InChI Key: MYWUZJCMWCOHBA-SECBINFHSA-N
1
N° of preparations All Preps | All Reactions 40 prep out of 59 reactions.
Available Data
N° of ref.
Identification Physical Data (21) Spectra (13) Bioactivity (47) Other Data (3)
74
Synthesize | Hide Details Find similar Chemical Names and Synonyms (R)-2-methylamino-1-phenylpropane, l-methamphetamine Identification Substance Label (23) Label
Reference
11
Dey, Soumen; Sudalai, Arumugam
Tetrahedron Asymmetry, 2015 , vol. 26, # 1 p. 67 - 72 Title/Abstract Full Text View citing articles Show Details
15
Lindqvist, Markus; Borre, Katja; Axenov, Kirill; Kótai, Bianka; Nieger, Martin; Leskelä, Markku; Pápai, Imre; Repo, Timo
Journal of the American Chemical Society, 2015 , vol. 137, # 12 p. 4038 - 4041 Title/Abstract Full Text View citing articles Show Details
Intermediate
GLAXOSMITHKLINE LLC; AXTEN, Jeffrey, Michael; BLACKLEDGE, Charles, William; BRADY, Gerald, Patrick; FENG, Yanhoug, G.; GRANT, Seth,
81
W.; MEDINA, Jesus, Rahul; MILLER, William, H.; ROMERIL, Stuart, P.
Patent: WO2010/59658 A1, 2010 ; Title/Abstract Full Text Show Details
2d
Colucid Pharmaceuticals, Inc.
Patent: US2010/256229 A1, 2010 ; Title/Abstract Full Text Show Details
6; M
COLUCID PHARMACEUTICALS, INC.; RUPNIAK, Nadia M.j.; WHITE, James F.
Patent: WO2010/9316 A1, 2010 ; Title/Abstract Full Text Show Details
10
Talluri, Siva Kumar; Sudalai, Arumugam
Tetrahedron, 2007 , vol. 63, # 39 p. 9758 - 9763 Title/Abstract Full Text View citing articles Show Details
R(-)-MA
Azzaro, Albert J.; Ziemniak, John; Kemper, Eva; Campbell, Bryan J.; Vandenberg, Chad
Journal of Clinical Pharmacology, 2007 , vol. 47, # 2 p. 146 - 158 Title/Abstract Full Text View citing articles Show Details
l(-); l-meth
Mendelson, John; Uemura, Naoto; Harris, Debra; Nath, Rajneesh P.; Fernandez, Emilio; Jacob III, Peyton; Everhart, E. Thomas; Jones, Reese T.
Clinical Pharmacology and Therapeutics, 2006 , vol. 80, # 4 p. 403 - 420 Title/Abstract Full Text View citing articles Show Details
I; Formula I
EMMELLEN BIOTECH PHARMACEUTICALS LIMITED
Patent: WO2006/67794 A1, 2006 ; Title/Abstract Full Text Show Details
6
Sention, Inc.
Patent: US2005/96387 A1, 2005 ; Title/Abstract Full Text Show Details
13b, R1=H, R2=CH3
Sayyed, Iliyas Ali; Sudalai, Arumugam
Tetrahedron Asymmetry, 2004 , vol. 15, # 19 p. 3111 - 3116 Title/Abstract Full Text View citing articles Show Details
(R)-(-)-MA
Kmecz, Ildiko; Simandi, Bela; Szekely, Edit; Fogassy, Elemer
Tetrahedron Asymmetry, 2004 , vol. 15, # 12 p. 1841 - 1845 Title/Abstract Full Text View citing articles Show Details
MA
Katagi; Tatsuno; Tsutsumi; Miki; Kamata; Nishioka; Nakajima; Nishikawa; Tsuchihashi
Xenobiotica, 2002 , vol. 32, # 9 p. 823 - 831 Title/Abstract Full Text View citing articles Show Details
Glezer, Sofia; Finberg, John P.M.
European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 173 - 177 Title/Abstract Full Text View citing articles Show Details
Merck12 623
Abu-Raya, Saleh; Tabakman, Rinat; Blaugrund, Eran; Trembovler, Victoria; Lazarovici, Philip
European Journal of Pharmacology, 2002 , vol. 434, # 3 p. 109 - 116 Title/Abstract Full Text View citing articles Show Details
MAMPH
Yeh, Geng-Chang; Chen, Jin-Chung; Tsai, Hsiu-Chuan; Wu, Hsueh-Hsia; Lin, Chao-Yu; Hsu, Ping-Ching; Peng, Yu-Chen
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 300, # 3 p. 1008 - 1016 Title/Abstract Full Text Show Details
L-MA
McCooeye, Margaret A.; Mester, Zoltan; Ells, Barbara; Barnett, David A.; Purves, Randy W.; Guevremont, Roger
Analytical Chemistry, 2002 , vol. 74, # 13 p. 3071 - 3075 Title/Abstract Full Text View citing articles Show Details
R(-)methamph
Bunzow; Sonders; Arttamangkul; Harrison; Zhang; Quigley; Darland; Suchland; Pasumamula; Kennedy; Olson; Magenis; Amara; Grandy
Molecular Pharmacology, 2001 , vol. 60, # 6 p. 1181 - 1188 Title/Abstract Full Text View citing articles Show Details
MET
Rohatagi, Shashank; Barrett, Jeffrey S.; McDonald, Lee J.; Morris, Esther M.; Darnow, John; DiSanto, Anthony R.
Pharmaceutical Research, 1997 , vol. 14, # 1 p. 50 - 55 Title/Abstract Full Text View citing articles Show Details
(R)-4
Crock, Piero Dalla; Ferraccioli, Raffaella; Rosa, Concetta L.A.
Gazzetta Chimica Italiana, 1996 , vol. 126, # 2 p. 107 - 109 Title/Abstract Full Text View citing articles Show Details
Glennon, Richard A.; Smith, J. Doyle; Ismaiel, Abd M.; El-Ashmawy, Mahmoud; Battaglia, George; Fisher, James B.
Journal of Medicinal Chemistry, 1991 , vol. 34, # 3 p. 1094 - 1098 Title/Abstract Full Text View citing articles Show Details
5
Label
Reference
16, R-(-)
Smith, Roger A.; White, Robert L.; Krantz, Allen
Journal of Medicinal Chemistry, 1988 , vol. 31, # 8 p. 1558 - 1566 Title/Abstract Full Text View citing articles Show Details
(R)-5a
Marco, Jose L.; Royer, Jacques; Husson, Henri-Philippe
Synthetic Communications, 1987 , vol. 17, # 6 p. 669 - 676 Title/Abstract Full Text Show Details
(R)-4a
Takashashi; Chida; Higashiyama; Onishi
Chemical and Pharmaceutical Bulletin, 1985 , vol. 33, # 11 p. 4662 - 4670 Title/Abstract Full Text View citing articles Show Details
Patent-Specific Data (3) Prophetic Compound
Related Markush Structure (RN)
Location in Patent
Reference Caron, Marc G.; Sotnikova, Tatyana D.; Gainetdinov, Raul R.
Patent: US2007/27208 A1, 2007 ;
11337200
Title/Abstract Full Text Show Details
BOEHRINGER INGELHEIM CHEMICALS INC
Patent: JP2005/507936 A, 2005 ;
prophetic product
Title/Abstract Full Text Show Details
Claim
Scaramuzzino, Giovanni
Patent: EP1336602 A1, 2003 ; Title/Abstract Full Text Show Details
Epstein, Mel; Wiig, Kjesten A.
Patent: US2002/115725 A1, 2002 ; Title/Abstract Full Text Show Details
Boehringer Ingelheim Chemicals, Inc.
Patent: US6399828 B1, 2002 ; Title/Abstract Full Text Show Details
Epstein, Mel H.; Wiig, Kjesten A.
Patent: US2003/119884 A1, 2003 ; Title/Abstract Full Text Show Details
Related Structure (1) Related Structure
Reference
Diese Konfiguration kommt dem E II 621 beschriebenen, in saurer Loesung linksdrehenden 2-Methylamino-1-phenyl-propan zu.
Wanag; Dombrowski
Chemische Berichte, 1942 , vol. 75, p. 82,86 Full Text Show Details
Derivative (2) Derivative
Reference
(R)-2-N-methylamino-1-phenylpropane hydrochloride
Noggle, F. Taylor; DeRuiter, Jack; Clark, C. Randall
Analytical Chemistry, 1986 , vol. 58, # 8 p. 1643 - 1648 Title/Abstract Full Text View citing articles Show Details
(R)-2-N-methylamino-1-phenylpropane hydrochloride
Takashashi; Chida; Higashiyama; Onishi
Chemical and Pharmaceutical Bulletin, 1985 , vol. 33, # 11 p. 4662 - 4670 Title/Abstract Full Text View citing articles Show Details
Purification (1) Purification (method)
Reference
purification via (+)-tartaric acid salt
Crock, Piero Dalla; Ferraccioli, Raffaella; Rosa, Concetta L.A.
Gazzetta Chimica Italiana, 1996 , vol. 126, # 2 p. 107 - 109 Title/Abstract Full Text View citing articles Show Details
Physical Data Boiling Point (3) Boiling Point
Pressure (Boiling Point)
Reference
39.3 - 40.2 °C
0.8 Torr
Jung et al.
Journal of the American Chemical Society, 1953 , vol. 75, p. 4664 Full Text View citing articles Show Details
77 - 79 °C
5 Torr
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Ogata
Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details
210 °C
Refractive Index (1) Refractive Index
Wavelength (Refractive Index)
Temperature (Refractive Index)
Reference
1.5097
589 nm
20 °C
Jung et al.
Journal of the American Chemical Society, 1953 , vol. 75, p. 4664 Full Text View citing articles Show Details
Density (1) Density
Measurement Temperature
Reference
0.9151 g·cm-3
16 °C
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Association (MCS) (2) Description (Association (MCS))
Partner (Association (MCS))
Solvent (Association (MCS))
NMR spectrum of the complex
(S)-2,2,2-trifluro-1(anthryl)ethanol
CDCl3
NMR spectrum of the complex
(R)-2,2,2-trifluoro-1(9-anthryl)ethanol
CDCl3
Temperature (Association (MCS))
28 °C
Comment (Association (MCS))
Reference
concentration dependence. Object(s) of Study: temperature dependence
Hanna, George M.
Pharmazie, 2006 , vol. 61, # 3 p. 188 - 193 Title/Abstract Full Text View citing articles Show Details
Hanna, George M.
Pharmazie, 2006 , vol. 61, # 3 p. 188 - 193 Title/Abstract Full Text View citing articles Show Details
Chromatographic Data (2) Chromatographic data
Location
Reference
HPLC (High performance liquid chromatography)
supporting information
Lindqvist, Markus; Borre, Katja; Axenov, Kirill; Kótai, Bianka; Nieger, Martin; Leskelä, Markku; Pápai, Imre; Repo, Timo
Journal of the American Chemical Society, 2015 , vol. 137, # 12 p. 4038 - 4041 Title/Abstract Full Text View citing articles Show Details
Sridar, Chitra; Kenaan, Cesar; Hollenberg, Paul F.
Drug Metabolism and Disposition, 2012 , vol. 40, # 12 p. 2256 - 2266 Title/Abstract Full Text View citing articles Show Details
LC (Liquid chromatography)
Circular Dichroism (1) Comment (Circular Dichroism)
Reference
Circular dichroism given
Anderson, Marcus; Wilcox, Katie; Guericke, Mike; Chu, Han; Wilson, Mark V.; Wilson, Erin; Lucas, Kerry; Holmes, Andrea E.
Chirality, 2010 , vol. 22, # 4 p. 398 - 402 Title/Abstract Full Text View citing articles Show Details
Crystal Property Description (3) Colour & Other Properties
Location
Kondekar, Nagendra B.; Kumar, Pradeep
Synthetic Communications, 2011 , vol. 41, # 9 p. 1301 - 1308 Title/Abstract Full Text View citing articles Show Details
colourless
light-yellow
Reference
Page/Page column 162
GLAXOSMITHKLINE LLC; AXTEN, Jeffrey, Michael; BLACKLEDGE, Charles, William; BRADY, Gerald, Patrick; FENG, Yanhoug, G.; GRANT, Seth, W.; MEDINA, Jesus, Rahul; MILLER, William, H.; ROMERIL, Stuart, P.
Patent: WO2010/59658 A1, 2010 ; Title/Abstract Full Text Show Details
EMMELLEN BIOTECH PHARMACEUTICALS LIMITED
Patent: WO2006/67794 A1, 2006 ;
light-yellow white
Title/Abstract Full Text Show Details
Optical Rotatory Power (8) Type (Optical Rotatory Power)
Concentration (Optical Rotatory Power)
Solvent (Optical Rotatory Power)
Optical Rotatory Power
Wavelength (Optical Rotatory Power)
Temperature (Optical Rotatory Power)
[alpha]
4.2 g/100ml
ethanol
-10.9 deg
589 nm
25 °C
Dey, Soumen; Sudalai, Arumugam
Tetrahedron Asymmetry, 2015 , vol. 26, # 1 p. 67 - 72 Title/Abstract Full Text View citing articles Show Details
[alpha]
0.4 g/100ml
ethanol
-10.2 deg
589 nm
25 °C
Kondekar, Nagendra B.; Kumar, Pradeep
Synthetic Communications, 2011 , vol. 41, # 9 p. 1301 - 1308 Title/Abstract Full Text View citing articles Show Details
[alpha]
1.0 g/100ml
ethanol
-10.87 deg
589 nm
25 °C
Talluri, Siva Kumar; Sudalai, Arumugam
Tetrahedron, 2007 , vol. 63, # 39 p. 9758 9763 Title/Abstract Full Text View citing articles Show Details
water hydrogen chloride
-17.6 -17.2 deg
589 nm
[alpha]
Reference
EMMELLEN BIOTECH PHARMACEUTICALS LIMITED
Patent: WO2006/67794 A1, 2006 ; Title/Abstract Full Text Show Details
[alpha]
2 g/100ml
ethanol
-10.6 deg
589 nm
20 °C
Crock, Piero Dalla; Ferraccioli, Raffaella; Rosa, Concetta L.A.
Gazzetta Chimica Italiana, 1996 , vol. 126, # 2 p. 107 - 109 Title/Abstract Full Text View citing articles Show Details
[alpha]
0.1 g/100ml
aq. HCl
-18.9 deg
589 nm
20 °C
Kozma; Madarasz; Acs; Fogassy
Tetrahedron Asymmetry, 1994 , vol. 5, # 2 p. 193 - 194 Title/Abstract Full Text View citing articles Show Details
[alpha]
4.20 g/100ml
ethanol
-10.9 deg
589 nm
21 °C
Smith, Roger A.; White, Robert L.; Krantz, Allen
Journal of Medicinal Chemistry, 1988 , vol. 31, # 8 p. 1558 - 1566 Title/Abstract Full Text View citing articles Show Details
neat (no solvent)
-2.75 deg
589 nm
[alpha]
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Spectra NMR Spectroscopy (8) Description (NMR Spectroscopy)
Nucleus (NMR Spectroscopy)
Chemical shifts
Solvents (NMR Spectroscopy)
Frequency (NMR Spectroscopy)
13C
chloroform-d1
50 MHz
Kondekar, Nagendra B.; Kumar, Pradeep
Synthetic Communications, 2011 , vol. 41, # 9 p. 1301 - 1308 Title/Abstract Full Text View citing articles Show Details
Dey, Soumen; Sudalai, Arumugam
Tetrahedron Asymmetry, 2015 , vol. 26, # 1 p. 67 - 72 Title/Abstract Full Text View citing articles Show Details
Chemical shifts
1H
chloroform-d1
200 MHz
Dey, Soumen; Sudalai, Arumugam
Tetrahedron Asymmetry, 2015 , vol. 26, # 1 p. 67 - 72 Title/Abstract Full Text View citing articles Show Details
Chemical shifts
1H
chloroform-d1
500 MHz
supporting information
Lindqvist, Markus; Borre, Katja; Axenov, Kirill; Kótai, Bianka; Nieger, Martin; Leskelä, Markku; Pápai, Imre; Repo, Timo
Journal of the American Chemical Society, 2015 , vol. 137, # 12 p. 4038 - 4041 Title/Abstract Full Text View citing articles Show Details
Chemical shifts
13C
chloroform-d1
126 MHz
supporting information
Lindqvist, Markus; Borre, Katja; Axenov, Kirill; Kótai, Bianka; Nieger, Martin; Leskelä, Markku; Pápai, Imre; Repo, Timo
Journal of the American Chemical Society, 2015 , vol. 137, # 12 p. 4038 - 4041 Title/Abstract Full Text View citing articles Show Details
Chemical shifts
1H
chloroform-d1
400 MHz
Kondekar, Nagendra B.; Kumar, Pradeep
Synthetic Communications, 2011 , vol. 41, # 9 p. 1301 - 1308 Title/Abstract Full Text View citing articles Show Details
Chemical shifts
13C
CDCl3
50 MHz
Talluri, Siva Kumar; Sudalai, Arumugam
Tetrahedron, 2007 , vol. 63, # 39 p. 9758 - 9763 Title/Abstract Full Text View citing articles Show Details
Chemical shifts
1H
CDCl3
200 MHz
Sayyed, Iliyas Ali; Sudalai, Arumugam
Tetrahedron Asymmetry, 2004 , vol. 15, # 19 p. 3111 - 3116 Title/Abstract Full Text View citing articles Show Details
Talluri, Siva Kumar; Sudalai, Arumugam
Tetrahedron, 2007 , vol. 63, # 39 p. 9758 - 9763 Title/Abstract Full Text View citing articles Show Details
CDCl3
200 MHz
Sayyed, Iliyas Ali; Sudalai, Arumugam
Tetrahedron Asymmetry, 2004 , vol. 15, # 19 p. 3111 - 3116 Title/Abstract Full Text View citing articles Show Details
1H
Coupling Nuclei
1H
Location
Reference
IR Spectroscopy (2) Description (IR Spectroscopy)
Solvent (IR Spectroscopy)
Reference
Bands
chloroform
Kondekar, Nagendra B.; Kumar, Pradeep
Synthetic Communications, 2011 , vol. 41, # 9 p. 1301 - 1308 Title/Abstract Full Text View citing articles Show Details
Dey, Soumen; Sudalai, Arumugam
Tetrahedron Asymmetry, 2015 , vol. 26, # 1 p. 67 - 72 Title/Abstract Full Text View citing articles Show Details
Bands
CHCl3
Talluri, Siva Kumar; Sudalai, Arumugam
Tetrahedron, 2007 , vol. 63, # 39 p. 9758 - 9763 Title/Abstract Full Text View citing articles Show Details
Mass Spectrometry (3) Description (Mass Spectrometry) liquid chromatography mass spectrometry (LCMS) electrospray ionisation (ESI) spectrum
Location
Reference Sridar, Chitra; Kenaan, Cesar; Hollenberg, Paul F.
Drug Metabolism and Disposition, 2012 , vol. 40, # 12 p. 2256 - 2266 Title/Abstract Full Text View citing articles Show Details
LCMS (Liquid chromatography mass spectrometry) ESI (Electrospray ionisation)
Page/Page column 162
GLAXOSMITHKLINE LLC; AXTEN, Jeffrey, Michael; BLACKLEDGE, Charles, William; BRADY, Gerald, Patrick; FENG, Yanhoug, G.; GRANT, Seth, W.; MEDINA, Jesus, Rahul; MILLER, William, H.; ROMERIL, Stuart, P.
Patent: WO2010/59658 A1, 2010 ; Title/Abstract Full Text Show Details
McCooeye, Margaret A.; Mester, Zoltan; Ells, Barbara; Barnett, David A.; Purves, Randy W.; Guevremont, Roger
Analytical Chemistry, 2002 , vol. 74, # 13 p. 3071 - 3075 Title/Abstract Full Text View citing articles Show Details
Sayyed, Iliyas Ali; Sudalai, Arumugam
Tetrahedron Asymmetry, 2004 , vol. 15, # 19 p. 3111 - 3116 Title/Abstract Full Text View citing articles Show Details
Talluri, Siva Kumar; Sudalai, Arumugam
Tetrahedron, 2007 , vol. 63, # 39 p. 9758 - 9763 Title/Abstract Full Text View citing articles Show Details
spectrum
Bioactivity Pharmacological Data (47) 1 of 47
Comment (Pharmacological Data)
Bioactivities present
Reference
Scaramuzzino, Giovanni
Patent: EP1336602 A1, 2003 ; Title/Abstract Full Text Show Details
LASSLO; WALLER; MEYER; SASTRY
Journal of medicinal and pharmaceutical chemistry, 1960 , vol. 2, p. 617 - 631 Title/Abstract Full Text View citing articles Show Details
Virginia Commonwealth University
Patent: US6057371 A1, 2000 ; Title/Abstract Full Text Show Details
Epstein, Mel; Wiig, Kjesten A.
Patent: US2002/115725 A1, 2002 ; Title/Abstract Full Text Show Details
Boehringer Ingelheim Chemicals, Inc.
Patent: US6399828 B1, 2002 ; Title/Abstract Full Text Show Details
Epstein, Mel H.; Wiig, Kjesten A.
Patent: US2003/119884 A1, 2003 ; Title/Abstract Full Text Show Details
BOEHRINGER INGELHEIM CHEMICALS INC
Patent: JP2005/507936 A, 2005 ; Title/Abstract Full Text Show Details
Sention, Inc.
Patent: US2005/96387 A1, 2005 ; Title/Abstract Full Text Show Details
EMMELLEN BIOTECH PHARMACEUTICALS LIMITED
Patent: WO2006/67794 A1, 2006 ; Title/Abstract Full Text Show Details
Caron, Marc G.; Sotnikova, Tatyana D.; Gainetdinov, Raul R.
Patent: US2007/27208 A1, 2007 ; Title/Abstract Full Text Show Details
Berry, Julianne; Chaudhry, Saeed M.; Sequeira, Joel; Kline, Lukeysha Charisse; D'Souza, Susan S.
Patent: US2007/202055 A1, 2007 ; Title/Abstract Full Text Show Details
Heinzelman; Aspergren
Journal of the American Chemical Society, 1953 , vol. 75, p. 925 Full Text View citing articles Show Details
Ogata
Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details
Zenitz; Macks; Moore
Journal of the American Chemical Society, 1947 , vol. 69, p. 1117,1120 Full Text Show Details
Wanag; Dombrowski
Chemische Berichte, 1942 , vol. 75, p. 82,86 Full Text Show Details
Jung et al.
Journal of the American Chemical Society, 1953 , vol. 75, p. 4664 Full Text View citing articles Show Details
Ose; Yoshimura
Yakugaku Zasshi, 1957 , vol. 77, p. 730,732 Chem.Abstr., 1957 , p. 17856 Full Text Show Details
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Kotake; Nakaminami
Proceedings of the Japan Academy, 1953 , vol. 29, p. 56 Full Text Show Details
Glennon, Richard A.; Smith, J. Doyle; Ismaiel, Abd M.; El-Ashmawy, Mahmoud; Battaglia, George; Fisher, James B.
Journal of Medicinal Chemistry, 1991 , vol. 34, # 3 p. 1094 - 1098 Title/Abstract Full Text View citing articles Show Details
2 of 47
3 of 47
Comment (Pharmacological Data)
Bioactivities present
Reference
Takashashi; Chida; Higashiyama; Onishi
Chemical and Pharmaceutical Bulletin, 1985 , vol. 33, # 11 p. 4662 - 4670 Title/Abstract Full Text View citing articles Show Details
Marco, Jose L.; Royer, Jacques; Husson, Henri-Philippe
Synthetic Communications, 1987 , vol. 17, # 6 p. 669 - 676 Title/Abstract Full Text Show Details
Smith, Roger A.; White, Robert L.; Krantz, Allen
Journal of Medicinal Chemistry, 1988 , vol. 31, # 8 p. 1558 - 1566 Title/Abstract Full Text View citing articles Show Details
Kozma; Madarasz; Acs; Fogassy
Tetrahedron Asymmetry, 1994 , vol. 5, # 2 p. 193 - 194 Title/Abstract Full Text View citing articles Show Details
Noggle, F. Taylor; DeRuiter, Jack; Clark, C. Randall
Analytical Chemistry, 1986 , vol. 58, # 8 p. 1643 - 1648 Title/Abstract Full Text View citing articles Show Details
Crock, Piero Dalla; Ferraccioli, Raffaella; Rosa, Concetta L.A.
Gazzetta Chimica Italiana, 1996 , vol. 126, # 2 p. 107 - 109 Title/Abstract Full Text View citing articles Show Details
Roberts, Stephen M.; Harbison, Raymond D.; James, Robert C.
Toxicology, 1995 , vol. 97, # 1-3 p. 49 - 57 Title/Abstract Full Text View citing articles Show Details
Knoll, Joseph; Miklya, Ildiko; Knoll, Berta; Marko, Raissa; Racz, Daniel
Life Sciences, 1996 , vol. 58, # 23 p. 2101 - 2114 Title/Abstract Full Text View citing articles Show Details
Rohatagi, Shashank; Barrett, Jeffrey S.; McDonald, Lee J.; Morris, Esther M.; Darnow, John; DiSanto, Anthony R.
Pharmaceutical Research, 1997 , vol. 14, # 1 p. 50 - 55 Title/Abstract Full Text View citing articles Show Details
Fotsch; Sonnenberg; Chen; Hale; Karbon; Norman
Journal of Medicinal Chemistry, 2001 , vol. 44, # 14 p. 2344 - 2356 Title/Abstract Full Text View citing articles Show Details
Katagi; Tatsuno; Tsutsumi; Miki; Kamata; Nishioka; Nakajima; Nishikawa; Tsuchihashi
Xenobiotica, 2002 , vol. 32, # 9 p. 823 - 831 Title/Abstract Full Text View citing articles Show Details
Abu-Raya, Saleh; Tabakman, Rinat; Blaugrund, Eran; Trembovler, Victoria; Lazarovici, Philip
European Journal of Pharmacology, 2002 , vol. 434, # 3 p. 109 - 116 Title/Abstract Full Text View citing articles Show Details
McCooeye, Margaret A.; Mester, Zoltan; Ells, Barbara; Barnett, David A.; Purves, Randy W.; Guevremont, Roger
Analytical Chemistry, 2002 , vol. 74, # 13 p. 3071 - 3075 Title/Abstract Full Text View citing articles Show Details
Scheinin, Harry; Anttila, Markku; Dahl, Marja-Liisa; Karnani, Hari; Nyman, Leena; Taavitsainen, Paeivi; Pelkonen, Olavi; Bertilsson, Leif
Clinical Pharmacology and Therapeutics, 1998 , vol. 64, # 4 p. 402 - 411 Title/Abstract Full Text View citing articles Show Details
Sayyed, Iliyas Ali; Sudalai, Arumugam
Tetrahedron Asymmetry, 2004 , vol. 15, # 19 p. 3111 - 3116 Title/Abstract Full Text View citing articles Show Details
Kmecz, Ildiko; Simandi, Bela; Szekely, Edit; Fogassy, Elemer
Tetrahedron Asymmetry, 2004 , vol. 15, # 12 p. 1841 - 1845 Title/Abstract Full Text View citing articles Show Details
Hanna, George M.
Pharmazie, 2006 , vol. 61, # 3 p. 188 - 193 Title/Abstract Full Text View citing articles Show Details
Partilla, John S.; Dempsey, Allison G.; Nagpal, Ameet S.; Blough, Bruce E.; Baumann, Michael H.; Rothman, Richard B.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 237 - 246 Title/Abstract Full Text View citing articles Show Details
Yeh, Geng-Chang; Chen, Jin-Chung; Tsai, Hsiu-Chuan; Wu, Hsueh-Hsia; Lin, Chao-Yu; Hsu, Ping-Ching; Peng, Yu-Chen
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 300, # 3 p. 1008 - 1016 Title/Abstract Full Text Show Details
Bunzow; Sonders; Arttamangkul; Harrison; Zhang; Quigley; Darland; Suchland; Pasumamula; Kennedy; Olson; Magenis; Amara; Grandy
Molecular Pharmacology, 2001 , vol. 60, # 6 p. 1181 - 1188 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
Bioactivities present
Reference
Glezer, Sofia; Finberg, John P.M.
European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 173 - 177 Title/Abstract Full Text View citing articles Show Details
Mendelson, John; Uemura, Naoto; Harris, Debra; Nath, Rajneesh P.; Fernandez, Emilio; Jacob III, Peyton; Everhart, E. Thomas; Jones, Reese T.
Clinical Pharmacology and Therapeutics, 2006 , vol. 80, # 4 p. 403 - 420 Title/Abstract Full Text View citing articles Show Details
Talluri, Siva Kumar; Sudalai, Arumugam
Tetrahedron, 2007 , vol. 63, # 39 p. 9758 - 9763 Title/Abstract Full Text View citing articles Show Details
Azzaro, Albert J.; Ziemniak, John; Kemper, Eva; Campbell, Bryan J.; Vandenberg, Chad
Journal of Clinical Pharmacology, 2007 , vol. 47, # 2 p. 146 - 158 Title/Abstract Full Text View citing articles Show Details
Sention, Inc.
Patent: US2003/232890 A1, 2003 ; Title/Abstract Full Text Show Details
COLUCID PHARMACEUTICALS, INC.; RUPNIAK, Nadia M.j.; WHITE, James F.
Patent: WO2010/9316 A1, 2010 ; Title/Abstract Full Text Show Details
GLAXOSMITHKLINE LLC; AXTEN, Jeffrey, Michael; BLACKLEDGE, Charles, William; BRADY, Gerald, Patrick; FENG, Yanhoug, G.; GRANT, Seth, W.; MEDINA, Jesus, Rahul; MILLER, William, H.; ROMERIL, Stuart, P.
Patent: WO2010/59658 A1, 2010 ; Title/Abstract Full Text Show Details
Anderson, Marcus; Wilcox, Katie; Guericke, Mike; Chu, Han; Wilson, Mark V.; Wilson, Erin; Lucas, Kerry; Holmes, Andrea E.
Chirality, 2010 , vol. 22, # 4 p. 398 - 402 Title/Abstract Full Text View citing articles Show Details
Verheijen, Jeroen C.; Wiig, Kjesten A.; Du, Shoucheng; Connors, Stacie L.; Martin, Ashley N.; Ferreira, Jennifer P.; Slepnev, Vladimir I.; Kochendoerfer, Ulrike
Bioorganic and Medicinal Chemistry Letters, 2009 , vol. 19, # 12 p. 3243 - 3246 Title/Abstract Full Text View citing articles Show Details
Colucid Pharmaceuticals, Inc.
Patent: US2010/256229 A1, 2010 ; Title/Abstract Full Text Show Details
Kondekar, Nagendra B.; Kumar, Pradeep
Synthetic Communications, 2011 , vol. 41, # 9 p. 1301 - 1308 Title/Abstract Full Text View citing articles Show Details
Lewin, Anita H.; Miller, Gregory M.; Gilmour, Brian
Bioorganic and Medicinal Chemistry, 2011 , vol. 19, # 23 p. 7044 - 7048 Title/Abstract Full Text View citing articles Show Details
Glennon
Mini-Reviews in Medicinal Chemistry, 2005 , vol. 5, # 10 p. 927 - 940 Title/Abstract Full Text View citing articles Show Details
Desai, Rajeev I.; Bergman, Jack
Journal of Pharmacology and Experimental Therapeutics, 2010 , vol. 335, # 3 p. 807 - 816 Title/Abstract Full Text View citing articles Show Details
Niwa, Toshiro; Murayama, Norie; Yamazaki, Hiroshi
Current Drug Metabolism, 2011 , vol. 12, # 5 p. 412 - 435 Title/Abstract Full Text View citing articles Show Details
Sridar, Chitra; Kenaan, Cesar; Hollenberg, Paul F.
Drug Metabolism and Disposition, 2012 , vol. 40, # 12 p. 2256 - 2266 Title/Abstract Full Text View citing articles Show Details
Turpeinen, Miia; Nieminen, Riina; Juntunen, Tarja; Taavitsainen, Paeivi; Raunio, Hannu; Pelkonen, Olavi
Drug Metabolism and Disposition, 2004 , vol. 32, # 6 p. 626 - 631 Title/Abstract Full Text View citing articles Show Details
Ramamoorthy; Tyndale; Sellers
Pharmacogenetics, 2001 , vol. 11, # 6 p. 477 - 487 Title/Abstract Full Text View citing articles Show Details
Lin; Di Stefano; Schmitz; Hsu; Ellis; Lennard; Tucker; Cho
Drug Metabolism and Disposition, 1997 , vol. 25, # 9 p. 1059 - 1064 Title/Abstract Full Text View citing articles Show Details
Glennon; Smith; Ismaiel; El-Ashmawy; Battaglia; Fischer
Journal of Medicinal Chemistry, 1991 , vol. 34, # 3 p. 1094 - 1098 Title/Abstract Full Text Show Details
4 of 47
Comment (Pharmacological Data)
Bioactivities present
Reference
Smith; White; Krantz
Journal of Medicinal Chemistry, 1988 , vol. 31, # 8 p. 1558 - 1566 Title/Abstract Full Text Show Details
Hiranita, Takato; Soto, Paul L.; Tanda, Gianluigi; Kopajtic, Theresa A.; Katz, Jonathan L.
Journal of Pharmacology and Experimental Therapeutics, 2013 , vol. 347, # 1 p. 20 - 29 Title/Abstract Full Text View citing articles Show Details
Lee, Sangkyu; Yoo, Hye Hyun; In, Moon Kyo; Jin, Changbae; Kim, Dong Hyun
Archives of Pharmacal Research, 2013 , vol. 36, # 11 p. 1385 - 1391 Title/Abstract Full Text View citing articles Show Details
N. Uemura, D. Harris, R.P. Nath, E. Fernandez, P. Jacob lll, E.T. Everhart, R.T. Jones and J. Mendelson
Clinical pharmacology and therapeutics, 2005 , vol. 77 Title/Abstract Full Text Show Details
Hiranita, Takato; Kohut, Stephen J.; Soto, Paul L.; Tanda, Gianluigi; Kopajtic, Theresa A.; Katz, Jonathan L.
Journal of Pharmacology and Experimental Therapeutics, 2014 , vol. 348, # 1 p. 174 - 191 Title/Abstract Full Text View citing articles Show Details
Reese, Edmund A.; Norimatsu, Yohei; Grandy, Madeline S.; Suchland, Katherine L.; Bunzow, James R.; Grandy, David K.
Journal of Medicinal Chemistry, 2014 , vol. 57, # 2 p. 378 - 390 Title/Abstract Full Text View citing articles Show Details
Taschwer, Magdalena; Seidl, Yvonne; Mohr, Stefan; Schmid, Martin G.
Chirality, 2014 , vol. 26, # 8 p. 411 - 418 Title/Abstract Full Text View citing articles Show Details
Dey, Soumen; Sudalai, Arumugam
Tetrahedron Asymmetry, 2015 , vol. 26, # 1 p. 67 - 72 Title/Abstract Full Text View citing articles Show Details
Astarita, Giuseppe; Avanesian, Agnesa; Grimaldi, Benedetto; Realini, Natalia; Justinova, Zuzana; Panlilio, Leight V.; Basit, Abdul; Goldberg, Steven R.; Piomelli, Daniele
PLoS ONE, 2015 , vol. 10, # 2 art. no. E0116961 Title/Abstract Full Text View citing articles Show Details
Lindqvist, Markus; Borre, Katja; Axenov, Kirill; Kótai, Bianka; Nieger, Martin; Leskelä, Markku; Pápai, Imre; Repo, Timo
Journal of the American Chemical Society, 2015 , vol. 137, # 12 p. 4038 - 4041 Title/Abstract Full Text View citing articles Show Details
The Board of Trustees of the University of Arkansas; Owens, Samuel M.; Carroll, Frank Ivy; Abraham, Philip
Patent: US9303092 B2, 2016 ; Title/Abstract Full Text Show Details
Amiri, Shayan; Amini-Khoei, Hossein; Mohammadi-Asl, Ali; Alijanpour, Sakineh; Haj-Mirzaian, Arya; Rahimi-Balaei, Maryam; Razmi, Ali; Olson, Carl O.; Rastegar, Mojgan; Mehdizadeh, Mehdi; Zarrindast, Mohammad- Reza
Physiology and Behavior, 2016 , vol. 163, p. 107 - 114 Title/Abstract Full Text View citing articles Show Details
Asimakopoulos, Alexandros G.; Kannan, Kurunthachalam
Environmental Chemistry, 2016 , vol. 13, # 4 p. 541 - 576 Title/Abstract Full Text View citing articles Show Details
Earla, Ravinder; Kumar, Santosh; Wang, Lei; Bosinger, Steven; Li, Junhao; Shah, Ankit; Gangwani, Mohitkumar; Nookala, Anantha; Liu, Xun; Cao, Lu; Jackson, Austin; Silverstein, Peter S.; Fox, Howard S.; Li, Weihua; Kumar, Anil
Drug Metabolism and Disposition, 2014 , vol. 42, # 12 p. 2097 - 2108 Title/Abstract Full Text Show Details
5 of 47
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
The Board of Trustees of the University of Arkansas; Owens, Samuel M.; Carroll, Frank Ivy; Abraham, Philip
Patent: US9303092 B2, 2016 ; Title/Abstract Full Text Show Details
6 of 47
7 of 47
8 of 47
9 of 47
10 of 47
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Hiranita, Takato; Kohut, Stephen J.; Soto, Paul L.; Tanda, Gianluigi; Kopajtic, Theresa A.; Katz, Jonathan L.
Journal of Pharmacology and Experimental Therapeutics, 2014 , vol. 348, # 1 p. 174 - 191 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Earla, Ravinder; Kumar, Santosh; Wang, Lei; Bosinger, Steven; Li, Junhao; Shah, Ankit; Gangwani, Mohitkumar; Nookala, Anantha; Liu, Xun; Cao, Lu; Jackson, Austin; Silverstein, Peter S.; Fox, Howard S.; Li, Weihua; Kumar, Anil
Drug Metabolism and Disposition, 2014 , vol. 42, # 12 p. 2097 - 2108 Title/Abstract Full Text Show Details
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Hiranita, Takato; Soto, Paul L.; Tanda, Gianluigi; Kopajtic, Theresa A.; Katz, Jonathan L.
Journal of Pharmacology and Experimental Therapeutics, 2013 , vol. 347, # 1 p. 20 - 29 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Lee, Sangkyu; Yoo, Hye Hyun; In, Moon Kyo; Jin, Changbae; Kim, Dong Hyun
Archives of Pharmacal Research, 2013 , vol. 36, # 11 p. 1385 - 1391 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
receptor; activation of
Species or TestSystem (Pharmacological Data)
RD-HGA16 cells; genetically modified/infected with: recombinant human TAAR1
11 of 47
12 of 47
13 of 47
14 of 47
Further Details (Pharmacological Data)
TAAR1: trace amine-associated receptor 1; effective concentration (EC); EC50 related to: human TAAR1
Type (Pharmacological Data)
EC50
Value of Type (Pharmacological Data)
3.3 μmol/l
Reference
Lewin, Anita H.; Miller, Gregory M.; Gilmour, Brian
Bioorganic and Medicinal Chemistry, 2011 , vol. 19, # 23 p. 7044 - 7048 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
receptor; activation of
Species or TestSystem (Pharmacological Data)
RD-HGA16 cells; genetically modified/infected with: recombinant human TAAR1
Further Details (Pharmacological Data)
TAAR1: trace amine-associated receptor 1
Results
molecular target: human TAAR1
Reference
Lewin, Anita H.; Miller, Gregory M.; Gilmour, Brian
Bioorganic and Medicinal Chemistry, 2011 , vol. 19, # 23 p. 7044 - 7048 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
receptor; activation of
Species or TestSystem (Pharmacological Data)
RD-HGA16 cells; genetically modified/infected with: recombinant rhesus monkey TAAR1
Further Details (Pharmacological Data)
TAAR1: trace amine-associated receptor 1; effective concentration (EC); EC50 related to: monkey TAAR1
Type (Pharmacological Data)
EC50
Value of Type (Pharmacological Data)
2.5 μmol/l
Reference
Lewin, Anita H.; Miller, Gregory M.; Gilmour, Brian
Bioorganic and Medicinal Chemistry, 2011 , vol. 19, # 23 p. 7044 - 7048 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
receptor; activation of
Species or TestSystem (Pharmacological Data)
RD-HGA16 cells; genetically modified/infected with: recombinant rhesus monkey TAAR1
Further Details (Pharmacological Data)
TAAR1: trace amine-associated receptor 1
Results
molecular target: monkey TAAR1
Reference
Lewin, Anita H.; Miller, Gregory M.; Gilmour, Brian
Bioorganic and Medicinal Chemistry, 2011 , vol. 19, # 23 p. 7044 - 7048 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
locomotor behaviors; effect on
Species or TestSystem (Pharmacological
DAT-KO mouse
Data) Sex
male and female
Method (Pharmacological Data)
Experimental We report here that the pharmacologic inhibition of the rate-limiting enzyme of DA synthesis, TH, almost immediately depletes brain DA to undetectable levels in DAT-KO mice and induces a transient recapitulation of essentially all PD symptoms for up to 16 h. DA-deficient DAT-KO mice (DDD mice) thus represent an acute PD model that is useful for studying the efficacy of compounds that potentially can restore control of locomotion in the absence of any contribution of the dopaminergic system. By using this approach, we found that several amphetamine derivatives can counteract the behavioral manifestations of severe DA deficiency, suggesting that, in addition to well-known DA-mediated effects, amphetamine-like compounds can also affect motor functions in a DA- and DAT-independent manner. Materials and Methods Animals. DAT-KO mice were generated as previously described [11]. Animal care was in accordance with the Guide for Care and Use of Laboratory Animals (National Institutes of Health publication No.865-23, Bethesda, Md., United States) with an approved protocol from the Duke University Institutional Animal Care and Use Committee. C57BL/6J3129Sv/J hybrid WT and DAT-KO mice, 3-5 mo old, of both sexes were used. None of animals used in these studies had the neurodegenerative phenotype sporadically observed in DAT-KO mice [60]. Drugs. Drugs or saline (0.9percent NaCl) were administered intraperitoneally (IP) or subcutaneously (SC) in a volume of 10 ml/kg. The drags were either from Sigma (St. Louis, Mo., United States) or supplied by the National Institute of Drug Abuse (NIDA). Drugs provided by the NIDA Drug Supply Program included: (+/-)-MDMA, (+)-MDMA, (+/-)-6-OH-MDA, (+/-)-MDA, (+/-)-MDE, (+)-MDE, ()-MDE, and AFT (alpha-ethyl-tryptamine acetate). Neurochemical assessments. Striatal tissue contents of DA and frontal cortical tissue levels of NE were assessed using HPLC-EC (high performance liquid chromatography with electrochemical detection) as described [8]. In vivo microdialysis measurements of striatal extracellular DA levels in freely moving mice were performed at least 24 h after implantation of a microdialysis probe as described previously [50]. Dialysate samples were assayed for DA using HPLC-EC. Behavioral methods. Locomotor activity of littermate WT and DATKO mice was measured in an Omnitech CCDigiscan (Accuscan Instruments, Columbus, Ohio United States) activity monitor under bright illumination [83]. All behavioral experiments were performed between 10:00 AM and 5:00 PM. Activity was measured at 5-min intervals, To evaluate the effects of drugs on motor behaviors, mice were placed into activity monitor chambers (20.x.20 cm) for 30 min and then treated with αMT (250 mg/kg IP). A drug or combination of drugs were injected 1 h after αMT administration, and various parameters of locomotor activity were monitored for up to 3 h. In cumulative dosing experiments, animals were treated with increasing doses of drugs after a 1-h interval. For the akinesia test, the mouse is held by the tail so that it is standing on forelimbs only and moving on its own. The number of steps taken with both forelimbs was recorded during a 30-s trial [57]. The presence of catalepsy was determined and measured by placing the animal's forepaws on a horizontal wooden bar (0.7 cm in diameter), 4 cm above the tabletop. The time until the mouse removed both forepaws from the bar was recorded, with a maximum cut-off time of 3 min [53]. In the grasping test of muscular rigidity, the mouse is suspended by its forelimbs on a metal rod (diameter: 0.25 cm) positioned approximately 20 cm above the table. The time the animal remains on the rod (maximum 1 min) was noted [58]. To assess rigidity in a bracing task, the number of steps taken with each forelimb when the mouse is pushed sideways over a distance of 50 cm was recorded [57]. Tremor was scored visually in mice using the rating scale [54]: 0, no tremor; 1, occasional isolated twi
Results
Akinesia test: ~6-20 number of steps; at Catalepsy test: ~90-180sec; at Grasping test: ~12-33 seconds time spent on the rod of the title compound administered after 1h of αMT treatment; figure is given
Location
Page/Page column 3; 12-15; sheet 9
Reference
Caron, Marc G.; Sotnikova, Tatyana D.; Gainetdinov, Raul R.
Patent: US2007/27208 A1, 2007 ; Title/Abstract Full Text Show Details
15 of 47
Effect (Pharmacological Data)
monoamine transporter; interaction with
Species or TestSystem (Pharmacological Data)
rat caudate putamen crude vesicular fraction
Method (Pharmacological Data)
vesicular fraction incubated with title comp. and 2 nmol/l <3H>DHTBZ for 4 h at 25 deg C; rapid filtration; liquid scintillation counting
Further Details (Pharmacological Data)
DHTBZ: dihydrotetrabenazine; VMAT2: vesicular monoamine transporter type 2; IC50 for title comp. inhibition of <3H>DHTBZ binding
Type (Pharmacological Data)
IC50
Value of Type (Pharmacological Data)
16 of 47
> 100 μmol/l
Reference
Partilla, John S.; Dempsey, Allison G.; Nagpal, Ameet S.; Blough, Bruce E.; Baumann, Michael H.; Rothman, Richard B.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 237 - 246 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
monoamine transporter; interaction with
Species or TestSystem (Pharmacological Data)
rat caudate putamen crude vesicular fraction
Method (Pharmacological Data)
vesicular fraction incubated with title comp. and 60 nmol/l <3H>dopamine for 5 min at 25 deg C; rapid filtration; liquid scintillation counting
Further Details
DHTBZ: dihydrotetrabenazine; VMAT : vesicular monoamine transporter type 2; IC50 for title comp. inhibition of <3H>dopamine uptake
2
(Pharmacological Data)
17 of 47
18 of 47
19 of 47
Type (Pharmacological Data)
IC50
Value of Type (Pharmacological Data)
19.3 μmol/l
Reference
Partilla, John S.; Dempsey, Allison G.; Nagpal, Ameet S.; Blough, Bruce E.; Baumann, Michael H.; Rothman, Richard B.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 237 - 246 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter releasing
Species or TestSystem (Pharmacological Data)
rat caudate putamen crude vesicular fraction
Method (Pharmacological Data)
vesicular fraction preloaded with 60 nmol/l <3H>tyramine for 20 min at 25 deg C, incubated with title comp. for 2 min at 25 deg C; rapid filtration; liquid scintillation counting; <3H>tyramine release evaluated
Further Details (Pharmacological Data)
EC50 and EMAX for title comp. inhibition of <3H>tyramine release
Type (Pharmacological Data)
EC50
Value of Type (Pharmacological Data)
27.4 μmol/l
Results
EMAX = 104 percent
Reference
Partilla, John S.; Dempsey, Allison G.; Nagpal, Ameet S.; Blough, Bruce E.; Baumann, Michael H.; Rothman, Richard B.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 237 - 246 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter releasing
Species or TestSystem (Pharmacological Data)
rat caudate putamen crude vesicular fraction
Method (Pharmacological Data)
vesicular fraction preloaded with 60 nmol/l <3H>dopamine for 20 min at 25 deg C, incubated with title comp. for 10 min at 25 deg C; rapid filtration; liquid scintillation counting; <3H>dopamine release evaluated
Further Details (Pharmacological Data)
EC50 and EMAX for title comp. inhibition of <3H>dopamine release
Type (Pharmacological Data)
EC50
Value of Type (Pharmacological Data)
34 μmol/l
Results
EMAX = 53.6 percent
Reference
Partilla, John S.; Dempsey, Allison G.; Nagpal, Ameet S.; Blough, Bruce E.; Baumann, Michael H.; Rothman, Richard B.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 237 - 246 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
human
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
0.25 - 0.5 mg/kg
Kind of Dosing (Pharmacological Data)
diluted with 0.9 percent sodium chloride to final volume of 10 ml; administered over 1 min, via infusion pump
Method (Pharmacological Data)
title comp. given to 12 subjects (title comp. abusers); plasma conc. of title comp. and metabolite l-amphetamine (l-AMPH) measured by gas chromatography-mass spectrometry for up to 48 h after dosing; pharmacokinetic analysis
Further Details (Pharmacological Data)
Cmax: maximum plasma conc.; AUC0-t: area under conc.-time curve up to last measurable conc.; CL: systemic clearance; Vd: volume of distribution
Results
0.25-0.5 mg/kg title comp.: title comp., l-AMPH Cmax = 65.4-125.9, 1.2-2.5 ng/ml, AUC0-t = 1072.2-2156.9, 32.1-83.5 ng*h/ml, t1/2 = 13.6-13.3, 64.6-43.6 h, resp., title comp. CL = 0.221-0.221 l/kg/h, Vd = 4.15-4.17 l/kg, resp. (table)
Metabolite (Pharmacological Data)
20 of 47
21 of 47
l-amphetamine [Reaxys RN: 2432739]
Reference
Mendelson, John; Uemura, Naoto; Harris, Debra; Nath, Rajneesh P.; Fernandez, Emilio; Jacob III, Peyton; Everhart, E. Thomas; Jones, Reese T.
Clinical Pharmacology and Therapeutics, 2006 , vol. 80, # 4 p. 403 - 420 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
hypertensive
Species or TestSystem (Pharmacological Data)
human
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
0.25 - 0.5 mg/kg
Kind of Dosing (Pharmacological Data)
diluted with 0.9 percent sodium chloride to final volume of 10 ml; administered over 1 min, via infusion pump
Method (Pharmacological Data)
title comp. given to 12 subjects (title comp. abusers); systolic (SBP) and diastolic blood pressure (DBP), heart rate (HR) measured with automatic noninvasive electronic device, respiratory rate (RR) counted manually up to 48 h
Further Details (Pharmacological Data)
placebo control
Results
title comp. increased SBP, DBP, HR, but not RR, effect significant for 0.5 mg/kg, compared with placebo; mean peak SBP, DBP, HR changes for 0.5 mg/kg (at ca. 5-15 min) were: 19.5 mm Hg, 12.8 mm Hg and 10.7 beats/min, resp. (table)
Reference
Mendelson, John; Uemura, Naoto; Harris, Debra; Nath, Rajneesh P.; Fernandez, Emilio; Jacob III, Peyton; Everhart, E. Thomas; Jones, Reese T.
Clinical Pharmacology and Therapeutics, 2006 , vol. 80, # 4 p. 403 - 420 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
hypothermic
Species or TestSystem (Pharmacological Data)
human
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
0.25 - 0.5 mg/kg
22 of 47
23 of 47
Kind of Dosing (Pharmacological Data)
diluted with 0.9 percent sodium chloride to final volume of 10 ml; administered over 1 min, via infusion pump
Method (Pharmacological Data)
title comp. given to 12 subjects (title comp. abusers); skin (ST) and tympanic (core) temperature (CT) measured with thermocouples on index finger and adjacent to tympanic membrane up to 48 h
Further Details (Pharmacological Data)
placebo control
Results
title comp. at 0.25, 0.5 mg/kg title comp. lowered ST by mean peak values of 3.9, 4.2 deg C, resp., effect significant compared with placebo; title comp. did not change CT (table)
Reference
Mendelson, John; Uemura, Naoto; Harris, Debra; Nath, Rajneesh P.; Fernandez, Emilio; Jacob III, Peyton; Everhart, E. Thomas; Jones, Reese T.
Clinical Pharmacology and Therapeutics, 2006 , vol. 80, # 4 p. 403 - 420 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
narcotic
Species or TestSystem (Pharmacological Data)
human
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
0.25 - 0.5 mg/kg
Kind of Dosing (Pharmacological Data)
diluted with 0.9 percent sodium chloride to final volume of 10 ml; administered over 1 min, via infusion pump
Method (Pharmacological Data)
title comp. given to 12 subjects (title comp. abusers); intoxication assessed by verbal ratings (VRs) and visual analog scales (VAS), subjective mood by Profile of Mood States up to 24-48 h
Further Details (Pharmacological Data)
placebo control
Results
title comp. caused increase in VRs and VAS of intoxication and in subjective mood (arousal); effects were significant for 0.5 mg/kg (table)
Reference
Mendelson, John; Uemura, Naoto; Harris, Debra; Nath, Rajneesh P.; Fernandez, Emilio; Jacob III, Peyton; Everhart, E. Thomas; Jones, Reese T.
Clinical Pharmacology and Therapeutics, 2006 , vol. 80, # 4 p. 403 - 420 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
toxicity
Species or TestSystem (Pharmacological Data)
human
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
0.25 - 0.5 mg/kg
Kind of Dosing (Pharmacological Data)
diluted with 0.9 percent sodium chloride to final volume of 10 ml; administered over 1 min, via infusion pump
Method (Pharmacological Data)
title comp. given to 12 subjects (title comp. abusers); biochemical tests, hematologic parameters, ECG, adverse events monitored up to 48 h
Further Details (Pharmacological Data)
placebo control
Comment
No effect
(Pharmacological Data)
24 of 47
25 of 47
26 of 47
Reference
Mendelson, John; Uemura, Naoto; Harris, Debra; Nath, Rajneesh P.; Fernandez, Emilio; Jacob III, Peyton; Everhart, E. Thomas; Jones, Reese T.
Clinical Pharmacology and Therapeutics, 2006 , vol. 80, # 4 p. 403 - 420 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
sympathomimetic
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat vas deferens
Sex
male
Concentration (Pharmacological Data)
0.83 - 8.3 μmol/l
Kind of Dosing (Pharmacological Data)
added to bath solution
Method (Pharmacological Data)
vasa deferentia stimulated with increasing conc. of noradrenaline or by methoxamine (1 μmol/l) in organ bath; title comp. added; contractile response measured
Further Details (Pharmacological Data)
further investigation with cocaine (30 μmol/l)
Results
title comp. increased sensitivity to noradreanaline by factors of 4.7-fold and 10-fold at doses 0.83 and 8.3 μmol/l, resp.; potentiation response was prevented by cocaine; no effect on methoxamine-induced contractions
Reference
Glezer, Sofia; Finberg, John P.M.
European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 173 - 177 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
sympathomimetic
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat vas deferens
Sex
male
Concentration (Pharmacological Data)
Ca. 1E-07 - 2E-05 mol/l
Kind of Dosing (Pharmacological Data)
added to bath every 5 min at increasing conc.
Method (Pharmacological Data)
vasa deferentia field-stimulated with 1-ms square-wave pulses at 0.1 Hz in organ bath; title comp. added; twitch responses isometrically measured
Further Details (Pharmacological Data)
further investigation with yohimbine and prazosin
Type (Pharmacological Data)
IC50
Value of Type (Pharmacological Data)
1.64 μmol/l
Results
title comp. at doses <= 1 μmol/l potentiated and at doses > 1 μmol/l inhibited twitch responses; inhibitory response was reversed by yohimbine; potentiation response was abolished by prazosin
Reference
Glezer, Sofia; Finberg, John P.M.
European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 173 - 177 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Long-Evans rat
Sex
male
Route of Application
intraperitoneal
Method (Pharmacological Data)
passive avoidance test; title comp. administered immediately after training; retention test 24 h later
Results
0.5 mg/kg of title comp.significantly improved task performance; step-through latency in response to title comp. was an inverted U-shaped dose response curve; significant improvement in memory performance relative to the saline group at doses of 0.25, 0.5, and 0.75 mg/kg
Location
Page 43-44
Reference
Sention, Inc.
Patent: US2003/232890 A1, 2003 ; Title/Abstract Full Text Show Details
27 of 47
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Long-Evans rat
Sex
male
Route of Application
intraperitoneal
Method (Pharmacological Data)
water maze test; title comp. administered immediately after training; retention test daily for 10 days
Results
significant enhancement in acquisition rate in animals administered 0.25 mg/kg of title comp.
Location
Page 44
Reference
Sention, Inc.
Patent: US2003/232890 A1, 2003 ; Title/Abstract Full Text Show Details
28 of 47
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Long-Evans rat
Sex
male
Route of Application
intraperitoneal
Method (Pharmacological Data)
locomotor activity levels measured by an automated motion detector for 3 h after title comp. administration
Results
only modest increases in activity at 0.5 mg/kg
Location
Page 44
Reference
Sention, Inc.
Patent: US2003/232890 A1, 2003 ; Title/Abstract Full Text Show Details
29 of 47
Effect (Pharmacological Data)
antinociceptive
Species or TestSystem (Pharmacological Data)
rat
Method
tail flick analgesia determined for up to 60 min after title comp. administration
(Pharmacological Data) Location
Page 45
Comment (Pharmacological Data)
No effect
Reference
Sention, Inc.
Patent: US2003/232890 A1, 2003 ; Title/Abstract Full Text Show Details
30 of 47
31 of 47
32 of 47
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
human
Sex
male
Route of Application
peroral
Kind of Dosing (Pharmacological Data)
1) single dose of 2.5 or 7.5 mg (FP Tablet 2.5(R)); 2) 5.0 mg/day twice-daily (2.5 mg each after breakfast and lunch) for 3 days; 3) six long-term patients (2.5 and 5 mg/day)
Method (Pharmacological Data)
6 healthy volunteers (27-54 years, 51-66 kg); single and repeat dosing experiments; urine collected for 4 and 6 days after dosing; solidphase extraction; high-performance liquid chromatography-electrospray ionization mass spectrometry
Further Details (Pharmacological Data)
FP Tablet 2.5(R) = selegiline hydrochloride
Results
time-course of urinary levels of title comp. (tables, diagrams)
Reference
Katagi; Tatsuno; Tsutsumi; Miki; Kamata; Nishioka; Nakajima; Nishikawa; Tsuchihashi
Xenobiotica, 2002 , vol. 32, # 9 p. 823 - 831 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
rat pheochromocytoma (PC12) cells
Concentration (Pharmacological Data)
1 μmol/l
Method (Pharmacological Data)
oxygen-glucose deprivation induced in nerve growth factor-differentiated cells by incub. in glucose-free DMEM (+14 percent serum; N2:CO2=95:5; 3 h) with title comp. and 1 μmol/l selegiline (SEL); then addition of glucose and reoxygenated (O2:CO2=95:5; 18 h)
Further Details (Pharmacological Data)
cell death measured by leakage of lactate dehydrogenase (LDH) into the medium; LDH activity determined spectrophotometrically by following NAD(+)->NADH conversion; 100 percent: cell death without title comp.; title comp. effect on SEL neuroprotection studied
Results
neuroprotective effect of SEL completely blocked (diagram)
Reference
Abu-Raya, Saleh; Tabakman, Rinat; Blaugrund, Eran; Trembovler, Victoria; Lazarovici, Philip
European Journal of Pharmacology, 2002 , vol. 434, # 3 p. 109 - 116 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
rat pheochromocytoma (PC12) cells
Concentration (Pharmacological Data)
0.1 - 10 μmol/l
Method
oxygen-glucose deprivation induced in nerve growth factor-differentiated cells by incub. in glucose-free DMEM (+14 percent serum; N2:CO2=95:5; 3 h) with title comp.; then addition of glucose and reoxygenated (O2:CO2=95:5; 18 h)
(Pharmacological Data)
33 of 47
34 of 47
35 of 47
Further Details (Pharmacological Data)
cell death measured by leakage of lactate dehydrogenase (LDH) into the medium; LDH activity determined spectrophotometrically by following NAD(+)->NADH conversion; 100 percent: cell death without title comp.
Results
ca. 70 percent increase of induced cell death at 1-10 μmol/l (diagram)
Reference
Abu-Raya, Saleh; Tabakman, Rinat; Blaugrund, Eran; Trembovler, Victoria; Lazarovici, Philip
European Journal of Pharmacology, 2002 , vol. 434, # 3 p. 109 - 116 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
secretion stimulant
Species or TestSystem (Pharmacological Data)
rat pheochromocytoma (PC12) cells
Concentration (Pharmacological Data)
1 - 10 μmol/l
Method (Pharmacological Data)
oxygen-glucose deprivation induced in nerve growth factor-differentiated cells by incub. in glucose-free DMEM (+14 percent serum; N2:CO2=95:5; 3 h) with title comp.; then addition of glucose and reoxygenated (O2:CO2=95:5; 18 h);
Further Details (Pharmacological Data)
prostaglandin (PG)E2 release determined by radioimmunoassay
Results
ca. 4-5-fold increase of induced PGE2 release at 1-10 μmol/l (diagram)
Reference
Abu-Raya, Saleh; Tabakman, Rinat; Blaugrund, Eran; Trembovler, Victoria; Lazarovici, Philip
European Journal of Pharmacology, 2002 , vol. 434, # 3 p. 109 - 116 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
cytoprotective
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat embryonal cortical cells
Concentration (Pharmacological Data)
0.1 - 1000 μmol/l
Method (Pharmacological Data)
cells exposed to 100 μmol/l N-methyl-D-aspartate and 10 μmol/l glycine in presence of title comp. for 30 min; 24 h later lactate dehydrogenase (LDH) measured using LDH-detecting kit
Further Details (Pharmacological Data)
reference comp.: MK-801, TCP, dextromethorphan (IC50 values were 0.11, 0.21, 33 μmol/l, resp.); further investigation in presence of dopamine receptor antagonists chloropromazine, haloperidol, and S(-)sulpride
Results
title comp. dose-dependently inhibited LDH accumulation at 100 - 1000 μmol/l; < 50 percent inhibition at 1000 μmol/l; no effect at 0.1 - 30 μmol/l; effect was not mediated through dopamine receptors (figures)
Reference
Yeh, Geng-Chang; Chen, Jin-Chung; Tsai, Hsiu-Chuan; Wu, Hsueh-Hsia; Lin, Chao-Yu; Hsu, Ping-Ching; Peng, Yu-Chen
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 300, # 3 p. 1008 - 1016 Title/Abstract Full Text Show Details
Effect (Pharmacological Data)
antagonist
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat embryonal cortical cells
Concentration (Pharmacological Data)
>= 10 μmol/l
Method (Pharmacological Data)
NMDA receptor assay; cells incubated with 0.1 Ci/ml 45Ca(2+), 100 μmol/l N-methyl-D-aspartate (NMDA), and 10 μmol/l glycine in presence of title comp. for 2 min; disrupted; radioactivity of cell solutions measured by liquid scintillation counter
Further Details (Pharmacological Data)
reference: MK-801, dextromethorphan, TCP, 2-amino-5-phosphopentanoic acid, 7-cholorkyneurenic acid (IC50 = 17 nmol/l, 1.8 μmol/l, 28 nmol/l, 12 and 0.21 μmol/l, resp.); further investigation in presence of chloropromazine, haloperidol, S(-)sulpride
36 of 47
37 of 47
38 of 47
Type (Pharmacological Data)
IC50
Value of Type (Pharmacological Data)
294 μmol/l
Results
title comp. sign. inhibited 45Ca(2+) accumulation; effect was not mediated through dopamine receptors (figures)
Reference
Yeh, Geng-Chang; Chen, Jin-Chung; Tsai, Hsiu-Chuan; Wu, Hsueh-Hsia; Lin, Chao-Yu; Hsu, Ping-Ching; Peng, Yu-Chen
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 300, # 3 p. 1008 - 1016 Title/Abstract Full Text Show Details
Effect (Pharmacological Data)
receptor blocking agent
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat embryonal cortical cells
Concentration (Pharmacological Data)
<= 3 μmol/l
Method (Pharmacological Data)
NMDA receptor assay; cells incubated with 0.1 Ci/ml 45Ca(2+), 100 μmol/l N-methyl-D-aspartate (NMDA), and 10 μmol/l glycine in presence of title comp. for 2 min; disrupted; radioactivity of cell solutions measured by liquid scintillation counter
Further Details (Pharmacological Data)
reference: MK-801, dextromethorphan, TCP, 2-amino-5-phosphopentanoic acid, 7-cholorkyneurenic acid (IC50 = 17 nmol/l, 1.8 μmol/l, 28 nmol/l, 12, and 0.21 μmol/l, resp.); further investigation in presence of chloropromazine, haloperidol, S(-)sulpride
Type (Pharmacological Data)
IC50
Value of Type (Pharmacological Data)
0.19 μmol/l
Results
title comp. sign. inhibited 45Ca(2+) accumulation; effect was not mediated through dopamine receptors (figures)
Reference
Yeh, Geng-Chang; Chen, Jin-Chung; Tsai, Hsiu-Chuan; Wu, Hsueh-Hsia; Lin, Chao-Yu; Hsu, Ping-Ching; Peng, Yu-Chen
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 300, # 3 p. 1008 - 1016 Title/Abstract Full Text Show Details
Effect (Pharmacological Data)
receptor blocking agent
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat cortical membranes
Sex
male
Concentration (Pharmacological Data)
0.01 - 1000 μmol/l
Method (Pharmacological Data)
NMDA receptor assay; membranes incubated with 100 μmol/l NMDA, 10 μmol/l glycine, and 2.5 nmol/l <3H>TCP at 25 deg C for 400 min; title comp. added for 60 min; filtered under vacuum; radioactivity measured by liquid scintillation counter
Further Details (Pharmacological Data)
NMDA: N-methyl-D-aspartate; <3H>TCP: <3H>N-<1-(2-thienyl)cyclohexyl> piperidine; reference comp.: 2-amino-5-phosphopentanoic acid and 7-cholorkyneurenic acid (no effect), or MK-801, TCP, and dextromethorphan (IC50 values 18, 33 and 2.1 μmol/l, resp.)
Type (Pharmacological Data)
IC50
Value of Type (Pharmacological Data)
Ca. 1000 μmol/l
Reference
Yeh, Geng-Chang; Chen, Jin-Chung; Tsai, Hsiu-Chuan; Wu, Hsueh-Hsia; Lin, Chao-Yu; Hsu, Ping-Ching; Peng, Yu-Chen
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 300, # 3 p. 1008 - 1016 Title/Abstract Full Text Show Details
Effect (Pharmacological Data)
receptor blocking agent
39 of 47
40 of 47
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat cortical membranes
Sex
male
Concentration (Pharmacological Data)
10 - 1000 μmol/l
Method (Pharmacological Data)
NMDA receptor assay; membranes incubated with 100 μmol/l NMDA, 10 μmol/l glycine, 2.5 nmol/l <3H>TCP, and title comp. at 25 deg C for 15 min; filtered under vacuum with cell harvester; radioactivity measured by liquid scintillation counter
Further Details (Pharmacological Data)
NMDA: N-methyl-D-aspartate; <3H>TCP: <3H>N-<1-(2-thienyl)cyclohexyl> piperidine; reference comp.: 2-amino-5-phosphopentanoic acid, 7-cholorkyneurenic acid, MK-801, TCP, dextromethorphan (IC50 values were 0.12, 7, 11, 0.97 μmol/l, resp.)
Type (Pharmacological Data)
IC50
Value of Type (Pharmacological Data)
215 μmol/l
Reference
Yeh, Geng-Chang; Chen, Jin-Chung; Tsai, Hsiu-Chuan; Wu, Hsueh-Hsia; Lin, Chao-Yu; Hsu, Ping-Ching; Peng, Yu-Chen
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 300, # 3 p. 1008 - 1016 Title/Abstract Full Text Show Details
Effect (Pharmacological Data)
receptor blocking agent
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat cortical membranes
Sex
male
Concentration (Pharmacological Data)
0.01 - 3 μmol/l
Method (Pharmacological Data)
NMDA receptor assay; membranes incubated with 100 μmol/l NMDA, 10 μmol/l glycine, 2.5 nmol/l <3H>TCP, and title comp. at 25 deg C for 15 min; filtered under vacuum with cell harvester; radioactivity measured by liquid scintillation counter
Further Details (Pharmacological Data)
NMDA: N-methyl-D-aspartate; <3H>TCP: <3H>N-<1-(2-thienyl)cyclohexyl> piperidine; reference comp.: 2-amino-5-phosphopentanoic acid, 7-cholorkyneurenic acid, MK-801, TCP, dextromethorphan (IC50 values were 0.12, 7, 11, 0.97 μmol/l, resp.)
Type (Pharmacological Data)
IC50
Value of Type (Pharmacological Data)
0.16 μmol/l
Reference
Yeh, Geng-Chang; Chen, Jin-Chung; Tsai, Hsiu-Chuan; Wu, Hsueh-Hsia; Lin, Chao-Yu; Hsu, Ping-Ching; Peng, Yu-Chen
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 300, # 3 p. 1008 - 1016 Title/Abstract Full Text Show Details
Effect (Pharmacological Data)
agonist
Species or TestSystem (Pharmacological Data)
HEK293 cells expressing rTAR1
Concentration (Pharmacological Data)
1 μmol/l
Method (Pharmacological Data)
cells incubated in KRH with 100 μmol/l 3-isobutyl-1-methylxanthine and title comp. for 1 h at 37 deg C; cAMP content measured using competitive binding of <3H>cAMP to a cAMP-binding protein
Further Details (Pharmacological Data)
HEK: human embryonic kidney; rTAR1: rat trace amine receptor 1; reference comp.: forskolin; KRH: Krebs-Ringer-HEPES buffer
41 of 47
42 of 47
43 of 47
Results
title comp. induced cAMP production acting as agonist (diagram)
Reference
Bunzow; Sonders; Arttamangkul; Harrison; Zhang; Quigley; Darland; Suchland; Pasumamula; Kennedy; Olson; Magenis; Amara; Grandy
Molecular Pharmacology, 2001 , vol. 60, # 6 p. 1181 - 1188 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
enzyme; inhib. of
Species or TestSystem (Pharmacological Data)
human liver microsomes
Concentration (Pharmacological Data)
1 - 1000 μmol/l
Method (Pharmacological Data)
microsomes incubated with title comp. in phosphate-buffered medium (pH 7.4, 37 deg C) containing dextromethorphan (substrate of DMDM, 100 mmol/l) for 20 min; CYP2D6 dextromethorphan O-demethylase (DMDM) activity determined; dextrorphan measured by HPLC
Further Details (Pharmacological Data)
reference comp. quinidine (IC50 = 0.41 μmol/l)
Type (Pharmacological Data)
IC50
Value of Type (Pharmacological Data)
414 μmol/l
Results
title comp. caused dose-dependent inhibition of CYP2D6 DMDM activity
Reference
Scheinin, Harry; Anttila, Markku; Dahl, Marja-Liisa; Karnani, Hari; Nyman, Leena; Taavitsainen, Paeivi; Pelkonen, Olavi; Bertilsson, Leif
Clinical Pharmacology and Therapeutics, 1998 , vol. 64, # 4 p. 402 - 411 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
psychotonic
Species or TestSystem (Pharmacological Data)
HSD Wistar rat
Sex
male and female
Route of Application
subcutaneous
Concentration (Pharmacological Data)
1 mg/kg
Kind of Dosing (Pharmacological Data)
used as hydrochloride
Method (Pharmacological Data)
8 rats (200-220 g); two-way conditioned avoidance reflex analyzed in shuttle box during 5 consecutive days; tetrabenazine*HCl (1 mg/kg, s.c.) and title comp. administered 1 h prior to testing performance of animals in shuttle box
Results
title comp. highly effective to antagonize depression effect of tetrabenazine in shuttle box (diagram)
Reference
Knoll, Joseph; Miklya, Ildiko; Knoll, Berta; Marko, Raissa; Racz, Daniel
Life Sciences, 1996 , vol. 58, # 23 p. 2101 - 2114 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
releasing hormones
Species or TestSystem (Pharmacological Data)
HSD Wistar rat brain stem
Sex
male
Concentration
10 mg/l
(Pharmacological Data)
44 of 47
45 of 47
Kind of Dosing (Pharmacological Data)
used as hydrochloride
Method (Pharmacological Data)
rats (280-350 g) stunned, brain stem excised, soaked in Krebs sol. at 37 deg C, <7,8-3H>noradrenaline (30-50 Ci/mmole) added for 45 min; brain stem stimulated with rectangular pulses; title comp. added to bathing fluid in presence of cocaine and DMI
Further Details (Pharmacological Data)
perfusates radioactivity determined by liquid scintillation counter; DMI: desmethylimipramine*HCl
Results
despite of continuous presence of cocaine in bath, title comp. highly potent enhancer of stimulation induced release of 3H-noradrenaline (diagram); 3H-noradrenaline released during resting period only modestly increased
Reference
Knoll, Joseph; Miklya, Ildiko; Knoll, Berta; Marko, Raissa; Racz, Daniel
Life Sciences, 1996 , vol. 58, # 23 p. 2101 - 2114 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
muscle contractive
Species or TestSystem (Pharmacological Data)
rabbit
Sex
male and female
Kind of Dosing (Pharmacological Data)
used as hydrochloride
Method (Pharmacological Data)
central ear artery of rabbit (2-3 kg)prepared, cannulated, mounted in organ bath (Krebs solution at 37 deg C); vasoconstriction elicited by field stimulation, intravasal pressure measured by electromanometer
Further Details (Pharmacological Data)
effect of title comp. measured in resting state and following stimulation
Results
title comp. caused dose related catecholaminergic activity enhancer effect; higher dose increased smooth muscle tone at resting state (graph)
Reference
Knoll, Joseph; Miklya, Ildiko; Knoll, Berta; Marko, Raissa; Racz, Daniel
Life Sciences, 1996 , vol. 58, # 23 p. 2101 - 2114 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
enzyme; examination of
Species or TestSystem (Pharmacological Data)
ICR mouse
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
15 mg/kg
Kind of Dosing (Pharmacological Data)
solut. title comp. in 10 ml/kg saline; control i.p. injection 10 ml/kg saline
Exposure Period (Pharmacological Data)
24 h
Method (Pharmacological Data)
adult ICR male mice; 30-35 g; administr. title comp.; killed; blood collected; serum alanine aminotransferase (ALT) activity determined according to Bergmeyer; compared with control
Results
mice treated title comp. had ALT activ. 30 IU/l; ALT activ. in control mice 24 IU/l
Comment (Pharmacological Data)
No effect
Reference
Roberts, Stephen M.; Harbison, Raymond D.; James, Robert C.
Toxicology, 1995 , vol. 97, # 1-3 p. 49 - 57 Title/Abstract Full Text View citing articles Show Details
46 of 47
47 of 47
Comment (Pharmacological Data)
affinity at σ binding sites (guinea pig cerebellar homogenate), does not bind at PCP sites
Reference
Glennon, Richard A.; Smith, J. Doyle; Ismaiel, Abd M.; El-Ashmawy, Mahmoud; Battaglia, George; Fisher, James B.
Journal of Medicinal Chemistry, 1991 , vol. 34, # 3 p. 1094 - 1098 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
reversible inhibition of bovine liver monoamine oxidase B, chirality influence
Reference
Smith, Roger A.; White, Robert L.; Krantz, Allen
Journal of Medicinal Chemistry, 1988 , vol. 31, # 8 p. 1558 - 1566 Title/Abstract Full Text View citing articles Show Details
Other Data Use (3) Use Pattern
Reference
nasal decongestant
Berry, Julianne; Chaudhry, Saeed M.; Sequeira, Joel; Kline, Lukeysha Charisse; D'Souza, Susan S.
Patent: US2007/202055 A1, 2007 ; Title/Abstract Full Text Show Details
nervous system stimulant
Sention, Inc.
Patent: US2003/232890 A1, 2003 ; Title/Abstract Full Text Show Details
Memory consolidation
Sention, Inc.
Patent: US2003/232890 A1, 2003 ; Title/Abstract Full Text Show Details